Highest-materiality recent filing
NeOnc reports Q1 net loss $8.8M; NEO212 Phase 1 complete, NEO100 interim data Aug 2026
Net loss $8.8M ($0.38/diluted) vs $32.3M ($1.78) in Q1 2025; G&A down to $489K, R&D up to $1.29M.
NeOnc Technologies raises $2M in stock and warrant offering for NEO216 preclinical trials
Initial closing of 277,777 shares and warrants at $7.20/share for ~$2M from one institutional investor.
NeOnc CEO buys ~$300k NTHI stock; FY2025 net loss $62M, mostly non-cash; clinical catalysts ahead
CEO Amir Heshmatpour purchased ~$300k of NTHI common stock in the past week, signaling confidence.
NeOnc Technologies enters ATM equity distribution agreement for up to $75M common stock
Agreement with BTIG, LLC and A.G.P./Alliance Global Partners for at-the-market offering up to $75M of common stock.
NeOnc Q4 net loss $62.1M ($3.20/sh); NEO212 Phase 1 complete, NEO100 Phase 2a enrolled
Q4 net loss $62.1M ($3.20 diluted EPS) vs $11.9M ($0.69) in Q4 2024; G&A surged to $4.8M from $1.7M.
NeOnc reports Phase 1 dose-escalation results for NEO212; RP2D set at 610 mg
MTD reached at 810 mg (Cohort 5) with second DLT; dose escalation halted.
New Securities Purchase Agreement for up to 746,973 shares at $7.20/share plus 5-yr warrants at $9.00/share.
NeOnc to present Phase 1 dose-escalation data from NEO212 trial on March 4 call
Investor conference call scheduled for March 4, 2026 at 9:00 a.m. ET to present initial Phase 1 dose-escalation results from NEO212-01 trial.
NeOnc Technologies raises $10M via private placement of 1.39M shares and warrants
Sold 1,388,888 shares at $7.20 and 1,388,888 warrants at $9.00 exercise to a single institutional investor for $10M.
6 of 25 patients (24%) achieved radiographic remission vs <8% historical salvage therapies.
NeOnc raises $1M from Saad Naja; AI study shows ultrasound boosts NEO100 against brain tumors
Issued 111,732 shares at $8.95 to Saad Naja, raising gross proceeds of ~$1M for working capital.
NeOnc Q3 net loss $8.6M ($0.45/diluted); NEO100 Phase 2a shows 21% response rate; board changes
Net loss of $8.6M ($0.45 diluted EPS) vs $2.2M ($0.12) in Q3 2024; G&A up $903k vs $244k YoY.
NEO100 yields 21% radiographic response & 44% 6mo PFS in recurrent IDH1-mutant gliomas
Radiographic response rate of 21% (5/24) in recurrent Grade III/IV IDH1-mutant astrocytoma, exceeding <8% benchmark for salvage therapies.
NeOnc Technologies appoints Amir Heshmatpour as CEO; founder Dr. Thomas Chen transitions to CMO/CSO
Dr. Thomas Chen resigns as CEO, becomes Chief Medical Officer and Chief Scientific Officer, retains Vice Chairman role.
Sheikh Nahyan bin Zayed Al Nahyan becomes Executive Chairman of NeOnc's Middle East subsidiary
Sheikh Nahyan bin Zayed Al Nahyan assumes Executive Chairman of NuroMENA Holdings Ltd., NeOnc's Middle East subsidiary.
NeOnc sets Oct 23 closing for $50M partnership with Quazar Investment after UAE approvals
Closing of $50M strategic partnership with Quazar Investment by Oct 23 after UAE tax/regulatory approvals.
MSA with IROS (affiliate of M42 and Mubadala) covers clinical research services in UAE for CNS cancer therapies.
NeOnc receives FDA authorization to proceed with Phase II clinical trial of NEO212 for brain cancer
FDA cleared NEO212-01 Phase IIa/IIb after Phase I showed safe dosing up to 810 mg daily days 1–5 of 28-day cycle.
NeOnc acquires JandB Holdings for ~120k shares; Q2 net loss $5.68M; $50M partnership finalised
Acquired 100% of JandB Holdings for ~120k shares of common stock valued at $25 per share.
NeOnc Technologies restates Q1 2025 financials due to RSU compensation error
Overstated non-cash share-based compensation on 1,486,667 RSUs issued Jan 4, 2024; assumed full vesting by Mar 31, 2025.
NeOnc Technologies restates Q1 2025 financials for overstated share-based compensation
Overstated non-cash share-based compensation expense on 1,486,667 RSUs issued Jan 4, 2024, due to incorrect assumption of full vesting by March 31, 2025.
NeOnc secures $2.5M NIH grants for NEO212; finalizes $50M Quazar partnership
Awarded two NIH STTR grants totaling $2.5M to advance NEO212 in gliomas and leukemia.
NeOnc signs $50M strategic partnership with Quazar and acquires AI/quantum IP for $3.5M
Quazar to acquire 1.4M NeOnc shares at $25/share ($35M); $15M for UAE clinical trials and infrastructure.
NeOnc to acquire patent from McMaster University in stock deal valued at ~$3M
Enters binding LOI to acquire all equity of new LLC from Dr. Ishwar Puri and Beth Levinson.
NeOnc Technologies executes sub-license for NEO100/NEO212 in MENA, milestone toward $50M Quazar deal
NeOnc executed sub-license agreement with its Abu Dhabi subsidiary NuroCure for NEO100 and NEO212, covering UAE, GCC, and MENA.
NeOnc Technologies raises $5M in convertible notes with 20% OID and short-term maturity
Issued $5,000,000 aggregate principal amount of convertible promissory notes to unaffiliated accredited investors.
NeOnc signs $50M non-binding term sheet with Quazar for UAE clinical platform expansion
$50M equity investment at $25/share from Quazar Investment; board approved June 30, 2025.
NeOnc Technologies appoints Dr. Josh Neman as Chief Clinical Officer
Dr. Josh Neman, PhD, appointed CCO; formerly Associate Professor at USC Keck School and Scientific Director of USC Brain Tumor Center.
NeOnc COO Patrick Walters retires June 1, 2025; no replacement announced
Patrick Walters notified the board on May 28, 2025 of his retirement as COO.
The Board of Directors (the “Board”) of the Company appointed Josh Neman as the Company’s Chief Clinical Officer, effective June 5, 2025.
On May 28, 2025, Patrick Walters notified the Board of Directors of NeOnc Technologies Holdings, Inc. (the “Company”) of his decision to retire as Chief Operating Officer of the Company effective June 1, 2025.
Max materiality 0.85 · Median 0.65 · Most common event other_material